HMX-T01 is HumiNex’s lead ADC candidate, developed using its proprietary antibody discovery and engineering technologies.
It is designed to achieve target-specific binding and efficient internalization to facilitate intracellular delivery of its cytotoxic payload, with the aim of developing a differentiated therapeutic option.